Evidence-based·Updated November 16, 2026·How we grade evidence

Carvedilol

MedicationBeta-blocker (prescription)

Carvedilol is one of the beta-blockers with the strongest survival evidence in heart failure: in large trials it cut deaths by about a third or more in people with a weak heart muscle, including severe heart failure, and it lowered deaths after a heart attack in people whose heart pumping was reduced. In a head-to-head trial it also lowered deaths more than immediate-release metoprolol tartrate. For supplements and drinks, the main concerns are energy drinks, which push blood pressure the other way; CBD, which blocks the CYP2D6 enzyme that clears carvedilol in lab studies; St. John's wort, which speeds the breakdown of many drugs; and celery products that add to blood pressure lowering.

Prescription medication: not a dietary supplement

This is an FDA-approved (or investigational) drug, not a supplement. It requires a prescription and medical supervision. The information below summarizes clinical-trial evidence for education only. It is not a recommendation to obtain or use it without a doctor.

Quick decision guide

May help most

Adults with chronic heart failure with reduced pumping strength, reduced heart function after a heart attack, or high blood pressure, treated and monitored by a prescriber

Common dosing range

Set by your prescriber and raised slowly. For heart failure, Coreg tablets start at 3.125 mg twice daily for 2 weeks and are increased step by step to as much as 25 mg twice daily; the Coreg CR capsule label starts at 10 mg once daily and goes up to 80 mg once daily

When to expect effects

Blood pressure falls within hours, and the label says the full blood pressure effect of a dose shows within 7 to 14 days. Survival benefit in heart failure trials appeared over months

Watch out for

Do not stop carvedilol suddenly: the label warns that abrupt stopping in people with heart artery disease has caused severe angina, heart attacks and dangerous heart rhythms, and says to taper over 1 to 2 weeks. It is contraindicated in asthma. Dizziness and fainting are most likely in the first hour after a dose when starting or raising it, so take it with food and avoid driving until you know how it affects you

What is it

Carvedilol is a prescription beta-blocker that also relaxes blood vessels, used for chronic heart failure, for reduced pumping strength of the heart after a heart attack, and for high blood pressure. It comes as Coreg and generic carvedilol tablets, taken twice a day, and as Coreg CR (carvedilol phosphate) extended-release capsules, taken once a day. Unlike atenolol and metoprolol, it blocks both beta-1 and beta-2 receptors (it is "nonselective") and also blocks alpha-1 receptors on blood vessels, so it can lower blood pressure more when standing than when lying down. The liver breaks it down, mainly through the enzymes CYP2D6 and CYP2C9, so some other medicines can raise or lower its level.

Is it worth it for you?

Use this as a quick fit check, not a diagnosis.

Worth considering if…

Your prescriber recommends a beta-blocker for heart failure with reduced ejection fraction, after a heart attack with reduced heart function, or for high blood pressure
You can take it regularly with food and know not to stop it suddenly
You are willing to share every medicine and supplement with your doctor or pharmacist, especially antidepressants, heart rhythm drugs, CBD and St. John's wort

Probably skip if…

You have asthma or a related bronchospastic condition: the label lists this as a contraindication and reports deaths from severe asthma attacks after single doses
You have second- or third-degree heart block, sick sinus syndrome or a very slow heart rate without a pacemaker, cardiogenic shock, or heart failure needing intravenous drugs: contraindicated
You have severe liver impairment: contraindicated, because levels rise 4 to 7 times
You have had a serious allergic reaction such as Stevens-Johnson syndrome, anaphylaxis or angioedema to carvedilol

Evidence at a glance

survival in mild to moderate heart failure

Good Evidence
Effect
65 percent lower risk of death over 6 to 12 months (3.2 versus 7.8 percent)
Best fit
Adults with symptomatic heart failure and an ejection fraction of 35 percent or less, on standard treatment
Time
Within months

survival in severe heart failure

Good Evidence
Effect
35 percent lower risk of death over about 10 months
Best fit
Adults with severe but stable heart failure and an ejection fraction below 25 percent
Time
Within months

survival compared with metoprolol tartrate in heart failure

Good Evidence
Effect
17 percent lower risk of death than metoprolol tartrate over about 5 years
Best fit
Adults with heart failure with reduced ejection fraction choosing among beta-blockers with their prescriber
Time
Assessed over a mean of 58 months

survival after a heart attack with reduced heart function

Limited Evidence
Effect
23 percent lower risk of death (12 versus 15 percent); the combined main endpoint was not significantly reduced
Best fit
Adults after a heart attack with an ejection fraction of 40 percent or less whose condition is stable
Time
Over about a year of follow-up

Evidence for 4 uses

AI-assisted evidence assessment. Talk to your doctor before relying on any single supplement.

survival in mild to moderate heart failure

Disease adjunct
Good Evidence

The U.S. Carvedilol Heart Failure program enrolled 1,094 people with chronic heart failure and an ejection fraction of 35 percent or less, already on digoxin, diuretics and an ACE inhibitor, and randomized them to carvedilol or placebo for 6 to 12 months. Deaths were 3.2 percent on carvedilol versus 7.8 percent on placebo, a 65 percent lower risk, and hospital stays for heart causes fell by 27 percent. The program was stopped early because of this difference. The label notes that death was not a primary endpoint of the individual trials, so the numbers need cautious reading, and later larger trials (below) confirmed a survival benefit.

Effect size
65 percent lower risk of death over 6 to 12 months (3.2 versus 7.8 percent)
Time to effect
Within months
Best fit
Adults with symptomatic heart failure and an ejection fraction of 35 percent or less, on standard treatment
Less likely
People with heart failure and a preserved ejection fraction, who were not studied

Bottom line: In a large trial program, carvedilol cut deaths sharply in heart failure with a weak heart muscle.

survival in severe heart failure

Disease adjunct
Good Evidence

COPERNICUS randomized 2,289 people with heart failure symptoms at rest or on minimal exertion and an ejection fraction below 25 percent, stable and without marked fluid retention, to carvedilol or placebo on top of standard treatment for a mean of 10.4 months. There were 130 deaths on carvedilol versus 190 on placebo, a 35 percent lower risk, and the combined risk of death or hospital stay fell by 24 percent. Fewer people on carvedilol than on placebo withdrew because of side effects or for other reasons. People needing intensive care, intravenous heart drugs or with marked fluid retention were excluded.

Effect size
35 percent lower risk of death over about 10 months
Time to effect
Within months
Best fit
Adults with severe but stable heart failure and an ejection fraction below 25 percent
Less likely
People in hospital with decompensated heart failure needing intravenous drugs, for whom the label contraindicates starting it

Bottom line: Carvedilol lowered deaths by about a third even in severe, stable heart failure.

survival compared with metoprolol tartrate in heart failure

Disease adjunct
Good Evidence

COMET randomized 3,029 people with chronic heart failure (NYHA class II to IV, ejection fraction below 35 percent) to carvedilol (target 25 mg twice daily) or immediate-release metoprolol tartrate (target 50 mg twice daily) for a mean of 58 months. Deaths were 34 percent on carvedilol versus 40 percent on metoprolol tartrate (hazard ratio 0.83); the combined rate of death or any hospital admission did not differ significantly (74 versus 76 percent). The comparison used metoprolol tartrate at a modest dose, not the extended-release metoprolol succinate proven in heart failure, so it does not show carvedilol is better than every beta-blocker used for heart failure.

Effect size
17 percent lower risk of death than metoprolol tartrate over about 5 years
Time to effect
Assessed over a mean of 58 months
Best fit
Adults with heart failure with reduced ejection fraction choosing among beta-blockers with their prescriber
Less likely
Not applicable to comparisons with extended-release metoprolol succinate, which was not tested

Bottom line: In one long trial, carvedilol lowered deaths more than immediate-release metoprolol tartrate.

survival after a heart attack with reduced heart function

Disease adjunct
Limited Evidence

CAPRICORN randomized 1,959 people who had a confirmed heart attack and an ejection fraction of 40 percent or less, already on modern treatment including ACE inhibitors, to carvedilol (raised to 25 mg twice daily) or placebo. The trial's main endpoint, death or hospital admission for heart causes, was not significantly lower (35 versus 37 percent). Deaths from any cause alone were lower: 12 percent on carvedilol versus 15 percent on placebo (hazard ratio 0.77), along with fewer heart deaths and repeat heart attacks. The FDA label bases the post-heart-attack indication on this trial.

Effect size
23 percent lower risk of death (12 versus 15 percent); the combined main endpoint was not significantly reduced
Time to effect
Over about a year of follow-up
Best fit
Adults after a heart attack with an ejection fraction of 40 percent or less whose condition is stable
Less likely
People after a heart attack with normal heart pumping, who were not studied

Bottom line: After a heart attack with a weakened heart, carvedilol lowered deaths in one trial, though its main combined goal was missed.

How it works

Carvedilol blocks beta receptors, the docking sites for adrenaline and noradrenaline on the heart, which slows the heart rate and eases its workload. Its alpha-1 blocking action widens blood vessels and lowers resistance to blood flow, which is why dizziness on standing is common when it is started or the dose goes up. The label says the reasons it helps in heart failure and after a heart attack are not fully established; in trials of heart failure, the heart's ejection fraction rose by about 9 percentage points on carvedilol versus 2 on placebo. Only about 25 to 35 percent of a dose reaches the bloodstream because the liver clears much of it on the first pass, and the half-life is about 7 to 10 hours. Taking it with food slows absorption without lowering the total amount absorbed, which reduces dizziness and fainting from a drop in blood pressure on standing. People whose CYP2D6 enzyme does not work have 2 to 3 times higher levels of one form of the drug and more dizziness while the dose is being raised. Levels are about 50 percent higher in older adults and 4 to 7 times higher in severe liver disease, where it must not be used.

How to take it

1. Typical dose
Your prescriber sets the dose and raises it in steps while watching for side effects. Coreg tablets (twice daily): for heart failure, 3.125 mg twice daily for 2 weeks, then 6.25, 12.5 and 25 mg twice daily at intervals of at least 2 weeks as tolerated (up to 50 mg twice daily has been given to people over 85 kg with mild to moderate heart failure); after a heart attack, 6.25 mg twice daily, increased after 3 to 10 days to 12.5 and then 25 mg twice daily; for high blood pressure, 6.25 mg twice daily, increased every 7 to 14 days to 12.5 and then 25 mg twice daily, with a total daily dose no higher than 50 mg. Coreg CR (once daily): for heart failure, 10 mg, then 20, 40 and 80 mg at intervals of at least 2 weeks; after a heart attack, 20 mg, then 40 and 80 mg; for high blood pressure, 20 mg, then 40 and 80 mg. The label says to lower the dose if the pulse falls below 55 beats per minute.
2. Higher studied dose
50 mg twice daily of the tablets in heavier people with mild to moderate heart failure; 80 mg once daily of Coreg CR.
3. Timing
Coreg tablets: twice daily. Coreg CR: once daily in the morning. Tablets and capsules are not swapped milligram for milligram; the Coreg CR label gives its own conversion from the twice-daily tablet dose.
4. With food
The labels say to take carvedilol with food, which slows absorption and lowers the chance of dizziness or fainting on standing. Coreg CR capsules should be swallowed whole, not crushed, chewed or split; they can be opened and the beads sprinkled on a spoonful of applesauce that is not warm and eaten right away.
5. Split dosing
Tablets are taken twice daily; Coreg CR is a once-daily capsule that must not be divided. Do not switch between them on your own
6. How long to try
Usually long term. The label says stopping should be done over 1 to 2 weeks with a prescriber's guidance

What to track

Dizziness or lightheadedness in the first hour after a dose, especially after starting or a dose increase
Resting pulse (the label lowers the dose below 55 beats per minute) and home blood pressure
Weight gain, swelling or worsening breathlessness, signs of fluid retention while the dose is raised
Blood sugar if you have diabetes, since carvedilol can hide the racing heart of a low and raise sugar in some people with heart failure
Wheezing or new breathing trouble
Any new medicine or supplement, checked with your pharmacist for CYP2D6 and CYP2C9 interactions

Bottom line: A prescriber sets and raises the dose slowly. Take it with food, never stop it suddenly, and check new antidepressants, heart drugs, CBD and St. John's wort with your pharmacist.

Safety

Know the common side effects, key cautions, and who should avoid it.

Common side effects

Dizziness (32 percent versus 19 percent on placebo in mild to moderate heart failure trials; 6 versus 5 percent in high blood pressure trials)Tiredness and weaknessSlow heart rate (9 versus 1 percent in heart failure trials) and low blood pressure (9 versus 3 percent)Diarrhea (12 versus 6 percent), nausea and vomitingHigher blood sugar (12 versus 8 percent) and weight gain (10 versus 7 percent) in heart failure trialsFluid retention and swelling, mainly while the dose is being raised

Serious risks

Who should avoid it

Pregnancy & breastfeeding

Pregnancy: the label says available data are not enough to know whether carvedilol raises the risk of birth defects or other harm, and that poorly controlled high blood pressure in pregnancy carries its own risks. Beta-blockers used in the third trimester may cause low blood pressure, a slow heart rate, low blood sugar and breathing problems in the newborn, so babies should be watched after birth. Breastfeeding: there are no data on carvedilol in human milk or its effects on a breastfed baby; it is present in the milk of rats, and the label asks that the benefits of breastfeeding be weighed with the mother's need for the drug. If you are pregnant, planning a pregnancy or breastfeeding, talk to your doctor.

Interactions

Energy drinksHigh

Energy drinks push blood pressure up, the opposite of what carvedilol does. In a crossover trial in 34 healthy young adults, drinking 32 oz of an energy drink within an hour raised blood pressure and lengthened the QTc interval of the heart rhythm more than placebo (up to about 18 to 20 ms versus 12 ms); the rise in heart rate was no larger than with placebo. No study has tested energy drinks in people taking carvedilol; one case report described a young woman on bisoprolol, another beta-blocker, who drank several energy drinks a day and had a fast heart rhythm that was hard to correct. Avoiding them is the cautious choice, especially with heart failure; review your caffeine use with your doctor or pharmacist.

Digoxin, verapamil, diltiazem or clonidineHigh

These drugs also slow the heart. The label says digoxin with carvedilol raises the risk of a slow heart rate and digoxin levels rise by about 15 percent, so digoxin should be monitored more closely; conduction problems have been seen with diltiazem; and with clonidine, carvedilol should be stopped first, with clonidine tapered several days later. Your prescriber plans and monitors these combinations.

St. John's wortModerate

St. John's wort speeds up drug-clearing enzymes: in 12 healthy volunteers, 14 days of it doubled the clearance of alprazolam through CYP3A4, though it did not change CYP2D6 activity. The Coreg label says carvedilol is cleared mainly by CYP2D6 and CYP2C9 and to a lesser extent CYP3A4, and that rifampin, a strong enzyme inducer, cut carvedilol levels by about 70 percent. No study has measured St. John's wort with carvedilol, so the size of any effect is unknown. Tell your prescriber before starting or stopping it, since a change in either direction could shift your blood pressure and heart rate.

CBD (cannabidiol)Moderate

In human liver enzyme studies, CBD was a potent blocker of CYP2D6, and the Coreg label says CYP2D6 blockers are expected to raise levels of the blood-vessel-relaxing form of carvedilol; people with low CYP2D6 activity had more dizziness while the dose was raised. Whether everyday CBD doses do this in people has not been tested. A single 600 mg dose of CBD also lowered resting systolic blood pressure by about 6 mmHg in 9 healthy men. Tell your prescriber if you use CBD and watch for dizziness, fainting or an unusually slow pulse.

Celery juice and celery seed extractModerate

In a 4-week randomized crossover trial in 52 people with high blood pressure, celery seed extract capsules (1.34 g a day) lowered 24-hour systolic pressure from 141.2 to 130.0 mmHg, with no change on placebo; celery juice itself has not been tested. Regular use could add to carvedilol's blood pressure lowering, which already makes dizziness on standing common. Check your home readings, watch for dizziness on standing, and review it with your doctor or pharmacist.

Drugs that raise carvedilol levels: CYP2D6 blockers (fluoxetine, paroxetine, quinidine, propafenone) and CYP2C9 blockers (amiodarone, fluconazole)Moderate

The label says strong CYP2D6 blockers have not been studied but are expected to raise carvedilol levels, and that amiodarone at least doubled levels of the beta-blocking form, which can slow the heart further or cause heart block; it names fluconazole as another CYP2C9 blocker with the same concern. Ask your pharmacist to check any new antidepressant, antifungal or heart rhythm medicine.

CyclosporineModerate

In 21 kidney transplant patients, starting carvedilol raised cyclosporine levels modestly; about 30 percent needed a lower cyclosporine dose, about 20 percent lower on average. The label advises close monitoring of cyclosporine levels after carvedilol is started, so make sure your transplant team knows.

Documented interactions

Choosing a product

What to look for on the label, and what to be skeptical of.

Look for…

An FDA-approved carvedilol product dispensed on your own prescription: Coreg or generic carvedilol tablets (twice daily) or Coreg CR extended-release capsules (once daily)
The form and strength printed clearly, since tablets and extended-release capsules are not swapped milligram for milligram
A pharmacy leaflet that says to take it with food and not to stop it suddenly

Be skeptical of…

St. John's wort or "natural mood" blends with no warning about drug interactions for people on heart medicines
CBD products claiming "no drug interactions": CBD blocks CYP2D6, an enzyme that clears carvedilol, in lab studies
Energy drinks or stimulant "pre-workout" products marketed as harmless for people with heart failure
Celery or other "natural blood pressure" products presented as safe add-ons or replacements for carvedilol

Frequently asked questions

Can I take St. John's wort with carvedilol?⌄

It has not been studied with carvedilol, but St. John's wort speeds up the enzymes that clear many drugs, and the carvedilol label shows that rifampin, a strong enzyme inducer, cut carvedilol levels by about 70 percent. Talk with your prescriber before starting it, and if you already take both, ask your prescriber before stopping it, since a change in either direction could shift your blood pressure and pulse.

Is CBD safe with carvedilol?⌄

It is not proven safe or unsafe. In lab studies CBD strongly blocks CYP2D6, one of the enzymes that clears carvedilol, and the label says blockers of that enzyme are expected to raise carvedilol levels, which can add to dizziness. CBD can also lower blood pressure a little. Tell your prescriber if you use it and report dizziness, fainting or an unusually slow pulse.

Can I drink energy drinks or coffee while taking carvedilol?⌄

Energy drinks are best avoided: in a trial of healthy young adults, a large energy drink raised blood pressure and changed the heart's electrical rhythm. Carvedilol itself has not been tested with energy drinks. Talk with your doctor or pharmacist about how much caffeine is reasonable for you, especially if you have heart failure.

Why do I have to take carvedilol with food?⌄

The label says food slows how fast carvedilol is absorbed without lowering the total amount, which reduces the drop in blood pressure on standing that can cause dizziness or fainting. This matters most when you start or your dose goes up. Coreg CR capsules are taken once daily in the morning with food.

Why does my dose go up so slowly?⌄

In heart failure, carvedilol is started at a low dose and raised every 2 weeks or more because fluid retention, low blood pressure and dizziness are most likely while the dose changes. The label says these episodes can usually be managed without stopping and do not prevent a good long-term response. Your prescriber decides each step.

Can I stop carvedilol if I feel fine?⌄

Do not stop it on your own. The label warns that stopping a beta-blocker suddenly has caused severe chest pain, heart attacks and dangerous heart rhythms in people with heart artery disease, and says carvedilol should be stopped over 1 to 2 weeks when possible, and that it may be prudent not to stop it abruptly even in people taking it for blood pressure or heart failure. Your prescriber will plan any change.

References by claim

survival in mild to moderate heart failure

Packer et al., 1996 · PubMed (1996) link

survival in severe heart failure

Packer et al., 2001 · PubMed (2001) link

survival after a heart attack with reduced heart function

Dargie et al., 2001 · PubMed (2001) link

survival compared with metoprolol tartrate in heart failure

Poole-Wilson et al., 2003 · PubMed (2003) link

Safety

Coreg (carvedilol) tablets prescribing information · DailyMed (FDA label) link

Interaction: Energy drinks

Shah et al., 2019 · PMC (2019) link

Aloraini et al., 2025 · PMC (2025) link

Interaction: St. John's wort

Markowitz et al., 2003 · PubMed (2003) link

Interaction: CBD (cannabidiol)

Yamaori et al., 2011 · PubMed (2011) link

Jadoon et al., 2017 · PMC (2017) link

Interaction: Celery juice and celery seed extract

Shayani Rad et al., 2022 · PubMed (2022) link

Track Carvedilol with Pilora

Set up dose reminders, check interactions, and join the community in the Pilora app.

Evidence-based·Updated Nov 16, 2026·Evidence current as of Nov 16, 2026·How we grade evidence

Disclaimer: This page summarizes published clinical-trial data for educational purposes and is not medical advice or a recommendation to use this prescription medication. Dosing, eligibility, and monitoring must be decided by a licensed prescriber.